Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › DFV890

DFV890

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of DFV890

5 trials tracked of DFV890.

5Trials tracked
0Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 2 5
  1. Phase 2 Study of Efficacy and Safety of DV890 in Patients With COVID-19 Pneumonia Completed
  2. Phase 2 Study of Efficacy, Safety and Tolerability of DFV890 in Patients With Knee Osteoarthritis Completed
  3. Phase 2 Study of Safety, Tolerability and Efficacy of DFV890 in Participants With Familial Cold Auto-inflammatory Syndrome (FCAS) Completed
  4. Phase 2 A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Elevated hsCRP Completed
  5. Phase 2 A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP) Completed

Showing the 5 most-cited and recently-updated of 5 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Phase 2a trial of DFV890 and MAS825 for inflammation in CHD/CHIP patients completes with 31 participants
Cardiology Phase II
Phase 2a trial of DFV890 and MAS825 for inflammation in CHD/CHIP patients completes with 31 participants Can two experimental drugs calm the dangerous inflammation linked to heart disease and a blood condition called CHIP?
A Phase 2a, multi-center, randomized, placebo-controlled, blinded study evaluated the efficacy, safety, and tolerability of DFV890 (oral dai…
A new trial tested two experimental drugs to safely turn down the dangerous inflammation driving heart disease in patients with CHIP.
CT.gov Mar 30, 2026